Home / Going-concern warnings / Hepion Pharmaceuticals, Inc.
Filed 2025-04-08 路 Form 10-K 路 Accession 0001641172-25-003250 nano
Price before filing: $0.44 (2025-04-07 close, split/dividend-adjusted)
Market cap at flag: $4.6M (2025-04-08) 路 Latest: $1.7M (2026-10-16)
| Window | HEPA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -10.5% | +12.0% | -22.5% | 2025-05-08 |
| 90 days | -83.6% | +23.4% | -107.1% | 2025-07-07 |
| 180 days | -79.5% | +33.9% | -113.5% | 2025-10-06 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As discussed in Note 2 to the financial statements, the Company's significant operating losses and negative cash flows from operations since inception raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: Grassi & Co., CPAs, P.C.
Source: independent auditor report in Form 10-K (period 2024-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.